---
title: "BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254340601.md"
description: "BETTA PHARMACEUTICALS announced that its clinical study for the postoperative adjuvant indication of ensartinib has made progress. The study was approved by the National Medical Products Administration in April 2022, and the recent interim analysis showed positive results, achieving the primary endpoint with significant statistical significance and clinical benefits. Detailed data will be presented at an international academic conference this year, and the company is accelerating the preparation of NDA application materials"
datetime: "2025-08-25T00:04:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254340601.md)
  - [en](https://longbridge.com/en/news/254340601.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254340601.md)
generator: "portal-rs"
---

# BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progress

BETTA PHARMACEUTICALS disclosed the progress of the clinical research on the postoperative adjuvant indication of ensartinib on the morning of August 25: In April 2022, the clinical trial for the hydrochloride capsule of ensartinib, submitted by the company for postoperative adjuvant treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer, was approved by the National Medical Products Administration. Recently, an independent data monitoring committee evaluated the clinical trial, and the interim analysis showed positive results, achieving the primary endpoint set for the study, with significant statistical significance and important clinical benefits. Detailed data from the study will be announced at a major international academic conference this year. The company's team is intensifying preparations for the submission materials to expedite the NDA application for the new indication

### Related Stocks

- [0BDYY.HK](https://longbridge.com/en/quote/0BDYY.HK.md)
- [300558.CN](https://longbridge.com/en/quote/300558.CN.md)

## Related News & Research

- [Bessent's bond gambit aimed at calming markets is instead stirring inflation worries](https://longbridge.com/en/news/296642975.md)
- [Trump’s Bond Buyback Push Puts Kevin Warsh in a Tough Spot — Peter Schiff Says Treasury ‘Pulled the Rug Out From Under’](https://longbridge.com/en/news/296615127.md)
- [Scott Bessent Brings His Hedge Fund Playbook To Treasury. The Bond Market Is Fighting Back](https://longbridge.com/en/news/296520391.md)
- [Novo Nordisk Stock And 2 Dividend Growers With Strong Cash Flow](https://longbridge.com/en/news/296635949.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**